Cette recherche s'applique uniquement aux ressources en bibliothèque.
4 résultats
Trier par:
Ajouter à la liste:

Facette sélectionnée


Étendre à toutes les références (sans texte intégral)
    • Article
    Sélectionner

    Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.

    Eriksson, Sophie, Bäck, Tom, Elgström, Erika, Jensen, Holger, Nilsson, Rune, Lindegren, Sture, Tennvall, Jan
    EJNMMI Research, 2013, Vol.3(1) [Revue évaluée par les pairs]
    SwePub (National Library of Sweden)
    Disponible
    Plus…
    Titre: Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.
    Auteur: Eriksson, Sophie; Bäck, Tom; Elgström, Erika; Jensen, Holger; Nilsson, Rune; Lindegren, Sture; Tennvall, Jan
    Sujet: Medicin Och Hälsovetenskap ; Klinisk Medicin ; Radiologi Och Bildbehandling ; Medical And Health Sciences ; Clinical Medicine ; Radiology, Nuclear Medicine And Medical Imaging ; Radioimmunotherapy ; Astatine-211 ; Targeted Alpha Therapy ; Colon Carcinoma
    Description: Most carcinomas are prone to metastasize despite successful treatment of the primary tumor. One way to address this clinical challenge may be targeted therapy with α-emitting radionuclides such as astatine-211 (211At). Radioimmunotherapy utilizing α-particle emitting radionuclides is considered especially suitable for the treatment of small cell clusters and single cells, although lesions of different sizes may also be present in the patient. The aim of this study was primarily to evaluate the toxicity and secondarily in vivo efficacy of a 211At-labeled monoclonal antibody (mAb) directed against colon carcinoma with tumor diameters of approximately 10 mm.
    Fait partie de: EJNMMI Research, 2013, Vol.3(1)
    Identifiant: 2191-219X (ISSN); 2191-219X (ISSN); 23557183 (PMID); 23557183 (PMID)

    • Article
    Sélectionner

    Successful radioimmunotherapy of established syngeneic rat colon carcinoma with ^sup 211^At-mAb

    Eriksson, Sophie, Bäck, Tom, Elgström, Erika, Jensen, Holger, Nilsson, Rune, Lindegren, Sture, Tennvall, Jan
    EJNMMI Research, Apr 2013, Vol.3(1), pp.1-9 [Revue évaluée par les pairs]
    © ProQuest LLC All rights reserved, Health & Medical Collection (Alumni edition), ProQuest Pharma Collection, Health & Medical Collection, Advanced Technologies & Aerospace Database, Publicly Available Content Database, ProQuest Central, ProQuest Advanced Technologies & Aerospace Collection, ProQuest Hospital Collection, ProQuest Technology Collection, Hospital Premium Collection (Alumni edition), ProQuest SciTech Collection, ProQuest Health & Medical Complete, ProQuest Central (new), ProQuest Central Korea, SciTech Premium Collection, Technology Collection, Health Research Premium Collection, Health Research Premium Collection (Alumni edition), ProQuest Central Essentials, ProQuest Central China, ProQuest One Academic
    Disponible
    Plus…
    Titre: Successful radioimmunotherapy of established syngeneic rat colon carcinoma with ^sup 211^At-mAb
    Auteur: Eriksson, Sophie; Bäck, Tom; Elgström, Erika; Jensen, Holger; Nilsson, Rune; Lindegren, Sture; Tennvall, Jan
    Description: Most carcinomas are prone to metastasize despite successful treatment of the primary tumor. One way to address this clinical challenge may be targeted therapy with [alpha]-emitting radionuclides such as astatine-211 (^sup 211^At). Radioimmunotherapy utilizing [alpha]-particle emitting radionuclides is considered especially suitable for the treatment of small cell clusters and single cells, although lesions of different sizes may also be present in the patient. The aim of this study was primarily to evaluate the toxicity and secondarily in vivo efficacy of a ^sup 211^At-labeled monoclonal antibody (mAb) directed against colon carcinoma with tumor diameters of approximately 10 mm. Eighteen rats with subperitoneal syngeneic colon carcinoma were allocated to three groups of six animals together with three healthy rats in each group. The groups were injected intravenously with either 150 [mu]g of unlabeled mAbs (controls) or 2.5 or 5 MBq ^sup 211^At-mAbs directed towards the Lewis Y antigen...
    Fait partie de: EJNMMI Research, Apr 2013, Vol.3(1), pp.1-9
    Identifiant: 2191219X (E-ISSN); 10.1186/2191-219X-3-23 (DOI)

    • Article
    Sélectionner

    Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211 At-mAb

    Eriksson, Sophie, Bäck, Tom, Elgström, Erika, Jensen, Holger, Nilsson, Rune, Lindegren, Sture, Tennvall, Jan
    EJNMMI Research, 2013, Vol.3(1), pp.1-9 [Revue évaluée par les pairs]
    Springer Science & Business Media B.V.
    Disponible
    Plus…
    Titre: Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211 At-mAb
    Auteur: Eriksson, Sophie; Bäck, Tom; Elgström, Erika; Jensen, Holger; Nilsson, Rune; Lindegren, Sture; Tennvall, Jan
    Sujet: Radioimmunotherapy ; Astatine-211 ; Targeted alpha therapy ; Colon carcinoma
    Fait partie de: EJNMMI Research, 2013, Vol.3(1), pp.1-9
    Identifiant: 2191-219X (E-ISSN); 10.1186/2191-219X-3-23 (DOI)

    • Article
    Sélectionner

    Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb

    Eriksson, Sophie E, Bäck, Tom, Elgström, Erika, Jensen, Holger, Nilsson, Rune, Lindegren, Sture, Tennvall, Jan
    EJNMMI research, 04 April 2013, Vol.3(1), pp.23 [Revue évaluée par les pairs]
    MEDLINE/PubMed (U.S. National Library of Medicine)
    Disponible
    Plus…
    Titre: Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb
    Auteur: Eriksson, Sophie E; Bäck, Tom; Elgström, Erika; Jensen, Holger; Nilsson, Rune; Lindegren, Sture; Tennvall, Jan
    Description: Most carcinomas are prone to metastasize despite successful treatment of the primary tumor. One way to address this clinical challenge may be targeted therapy with α-emitting radionuclides such as astatine-211 (211At). Radioimmunotherapy utilizing α-particle emitting radionuclides is considered especially suitable for the treatment of small cell clusters and single cells, although lesions of different sizes may also be present in the patient. The aim of this study was primarily to evaluate the toxicity and secondarily in vivo efficacy of a 211At-labeled monoclonal antibody (mAb) directed against colon carcinoma with tumor diameters of approximately 10 mm. Eighteen rats with subperitoneal syngeneic colon carcinoma were allocated to three groups of six animals together with three healthy rats in each group. The groups were injected intravenously with either 150 μg of unlabeled mAbs (controls) or 2.5 or 5 MBq 211At-mAbs directed towards the Lewis Y antigen expressed on the cell membrane of several carcinomas. Tumor volume, body weight, and blood cell counts were monitored for 100 days after treatment. Local tumors were non-palpable in five out of six rats after treatment with both activities of 211At-mAbs, compared to one out of six in the control group. At the study end, half of the animals in each group given 211At-BR96 and one animal in the control group were free from disease. Radioimmunotherapy resulted in dose-dependent, transient weight loss and myelotoxicity. Survival was significantly better in the groups receiving targeted alpha therapy than in those receiving unlabeled mAbs. This study demonstrates the possibility of treating small, solid colon carcinoma tumors with α-emitting radionuclides such as 211At bound to mAbs, with tolerable toxicity.
    Fait partie de: EJNMMI research, 04 April 2013, Vol.3(1), pp.23
    Identifiant: 2191-219X (ISSN); 23557183 Version (PMID); 10.1186/2191-219X-3-23 (DOI)